Needham Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $68

Needham analyst Ami Fadia has initiated coverage on LB Pharmaceuticals (NASDAQ: LBRX) with a Buy rating. The analyst has set a price target of $68 for the company's stock.